Evidence · Randomised trial
Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: A randomized controlled trial.
- Allied health
- Breast milk and breastfeeding
- Bronchopulmonary dysplasia
- Cardiovascular
- Eyes and hearing
- Growth
- Medical
- Necrotising enterocolitis
- Nutrition and gastrointestinal
- Parenteral nutrition
- Patent ductus arteriosus
- Respiratory
- Retinopathy of prematurity
This paper is from 2017, more than five years ago. Newer evidence may have been published since.
Summary
Randomised controlled trial in 90 extremely preterm infants comparing a fish oil-containing parenteral lipid emulsion (SMOFlipid) with an olive oil-based emulsion (Clinoleic). The trial measured serial serum phospholipid and breast milk fatty acid profiles alongside retinopathy of prematurity, bronchopulmonary dysplasia, necrotising enterocolitis, patent ductus arteriosus, sepsis and growth to 36 weeks' postmenstrual age. The fish oil emulsion raised EPA substantially and DHA marginally, and lowered arachidonic acid and the AA to DHA ratio. Morbidities and growth did not differ between groups, and the authors call for studies of longer or different DHA and AA supplementation.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.